Danaher (NYSE: DHR) reported Q4 EPS of $1.28, $0.03 better than the analyst estimate of $1.25. Revenue for the quarter came in at $4.9 billion versus the consensus estimate of $4.8 billion.

Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "Our fourth quarter results wrapped up a tremendous 2019 for Danaher. For the full year, we achieved 6.0% core revenue growth with solid margin expansion and cash flow. We continued to capture market share in many of our businesses through new product innovation and enhanced commercial execution. In addition, we completed the split-off of our Dental platform in December and announced the pending acquisition of GE's Biopharma business."

Joyce added, "Through a combination of organic and inorganic initiatives, we have transformed Danaher into a higher growth, higher margin and higher recurring revenue company with leading positions in attractive end-markets. Our portfolio today -combined with the power of the Danaher Business System - positions us well to continue to deliver long-term shareholder value."

GUIDANCE:

Danaher sees Q1 2020 EPS of $1.06-$1.09, versus the consensus of $1.04.

Danaher sees FY2020 EPS of $4.80-$4.90, versus the consensus of $5.34.

• For the first quarter 2020, the Company anticipates that diluted net earnings per share will be in the range of $0.78 to $0.81 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.06 to $1.09.
• For the full year 2020, the Company anticipates that diluted net earnings per share will be in the range of $3.96 to $4.06 and non-GAAP adjusted diluted net earnings per share will be $4.80 to $4.90, which assumes non-GAAP core revenue growth of approximately 5.0%. These first quarter and full year 2020 estimated results do not include the impact of earnings from the pending GE Biopharma acquisition, which is expected to close in the first quarter of 2020.

For earnings history and earnings-related data on Danaher (DHR) click here.